[go: up one dir, main page]

SV2018005614A - Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias - Google Patents

Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias

Info

Publication number
SV2018005614A
SV2018005614A SV2018005614A SV2018005614A SV2018005614A SV 2018005614 A SV2018005614 A SV 2018005614A SV 2018005614 A SV2018005614 A SV 2018005614A SV 2018005614 A SV2018005614 A SV 2018005614A SV 2018005614 A SV2018005614 A SV 2018005614A
Authority
SV
El Salvador
Prior art keywords
interleucine
receiver
inflammatory diseases
treat inflammatory
peptidic inhibitors
Prior art date
Application number
SV2018005614A
Other languages
English (en)
Inventor
Ashok Bhandari
Gregory Bourne
Xiaoli Cheng
Brian Troy Frederick
Jie Zhang
Dinesh V Patel
David Liu
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of SV2018005614A publication Critical patent/SV2018005614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA INHIBIDORES PEPTÍDICOS NOVEDOSOS DEL RECEPTOR DE INTERLEUCINA 23 Y COMPOSICIONES Y MÉTODOS RELACIONADOS PARA UTILIZAR ESTOS INHIBIDORES PEPTÍDICOS PARA EL TRATAMIENTO O LA PREVENCIÓN DE DIVERSAS ENFERMEDADES Y TRASTORNOS, INCLUIDAS ENFERMEDADES INTESTINALES INFLAMATORIAS.
SV2018005614A 2015-07-15 2018-01-15 Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias SV2018005614A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
SV2018005614A true SV2018005614A (es) 2018-05-22

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005614A SV2018005614A (es) 2015-07-15 2018-01-15 Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias

Country Status (23)

Country Link
EP (1) EP3341011A4 (es)
JP (1) JP6858174B2 (es)
KR (1) KR102513978B1 (es)
CN (1) CN108348580B (es)
AU (1) AU2016293619B2 (es)
BR (1) BR112018000691A2 (es)
CA (1) CA2991984A1 (es)
CL (3) CL2018000128A1 (es)
CO (1) CO2018000349A2 (es)
CR (1) CR20180029A (es)
DO (1) DOP2018000010A (es)
EA (1) EA035733B9 (es)
EC (1) ECSP18002929A (es)
HK (1) HK1257747A1 (es)
IL (1) IL256827A (es)
MX (1) MX384213B (es)
NI (1) NI201800008A (es)
PE (1) PE20180571A1 (es)
PH (1) PH12018500086A1 (es)
SG (1) SG10201912066SA (es)
SV (1) SV2018005614A (es)
UA (1) UA123772C2 (es)
WO (1) WO2017011820A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20170028307A (ko) 2014-05-16 2017-03-13 프로타고니스트 테라퓨틱스, 인코포레이티드 α4β7 인테그린 티오에테르 펩티드 길항제
SG11201700327WA (en) 2014-07-17 2017-02-27 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
JP7670605B2 (ja) * 2018-07-12 2025-04-30 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
CA3145449A1 (en) * 2019-07-01 2021-01-07 Valitor, Inc. Hydrophilic linkers for multivalent peptide conjugates
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022000397A (es) * 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202515892A (zh) * 2020-01-15 2025-04-16 美商健生生物科技公司 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
WO2021146454A1 (en) * 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL299529A (en) * 2020-06-29 2023-02-01 Univ Washington Human il23 receptor binding polypeptides
CN116438456A (zh) 2020-09-11 2023-07-14 格里姆普斯生物股份有限公司 用于疾病检测/诊断、分期、监测和治疗的离体蛋白酶活性检测
KR20230110570A (ko) * 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
UY39858A (es) * 2021-07-14 2023-02-28 Janssen Biotech Inc Inhibidores peptídicos bicíclicos del receptor de interleucina-23
WO2023288028A2 (en) * 2021-07-14 2023-01-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor
WO2023099669A1 (en) 2021-12-01 2023-06-08 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
IL317902A (en) 2022-06-30 2025-02-01 Sanofi Sa New peptides as selective antagonists of the IL-23 receptor
EP4622991A2 (en) * 2022-11-21 2025-10-01 Janssen Pharmaceutica NV Synthesis of a cyclic peptide
EP4652181A1 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Polycyclic peptide inhibitors of interleukin-23 receptor
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
AU2024214418A1 (en) 2023-01-31 2025-09-18 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor
WO2024227437A1 (zh) * 2023-05-04 2024-11-07 西藏海思科制药有限公司 白介素-23受体的肽抑制剂制备及其用途
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2025051912A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
WO2025051920A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2011501941A (ja) * 2007-07-06 2011-01-20 バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ Ｉｌ−２３レセプターのアンタゴニストおよびその使用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US9523073B2 (en) * 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
SG11201700327WA (en) * 2014-07-17 2017-02-27 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Also Published As

Publication number Publication date
EA201890325A1 (ru) 2018-06-29
CL2018003322A1 (es) 2019-01-18
JP2018522008A (ja) 2018-08-09
EA035733B1 (ru) 2020-07-31
PE20180571A1 (es) 2018-04-04
CL2018000128A1 (es) 2018-06-15
DOP2018000010A (es) 2018-03-30
CO2018000349A2 (es) 2018-07-10
AU2016293619B2 (en) 2021-02-25
EP3341011A4 (en) 2019-02-20
HK1259149A1 (zh) 2019-11-29
WO2017011820A3 (en) 2017-02-23
CN108348580B (zh) 2022-05-10
ECSP18002929A (es) 2018-03-31
KR20180030663A (ko) 2018-03-23
CL2021000343A1 (es) 2021-08-06
SG10201912066SA (en) 2020-02-27
WO2017011820A2 (en) 2017-01-19
IL256827A (en) 2018-03-29
HK1257747A1 (zh) 2019-10-25
CN108348580A (zh) 2018-07-31
UA123772C2 (uk) 2021-06-02
EA035733B9 (ru) 2021-01-14
EP3341011A2 (en) 2018-07-04
JP6858174B2 (ja) 2021-04-14
MX2018000542A (es) 2018-06-27
PH12018500086A1 (en) 2018-07-30
CR20180029A (es) 2018-06-05
KR102513978B1 (ko) 2023-03-27
CA2991984A1 (en) 2017-01-19
BR112018000691A2 (pt) 2018-09-18
AU2016293619A1 (en) 2018-02-01
MX384213B (es) 2025-03-14
NI201800008A (es) 2018-06-29

Similar Documents

Publication Publication Date Title
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX387661B (es) Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas.
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2018007408A (es) Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes.
DOP2017000136A (es) Compuestos para tratar el cáncer
UY35730A (es) Composiciones farmacéuticas comprendiendo kisspeptin o sus derivados